Sharps Technology Appoints Justin Page as Vice President of Technical Operations
February 09 2023 - 8:21AM
Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS”
and “STSSW”), an innovative medical device and drug delivery
Company offering patented, best-in-class syringe products, appoints
Justin Page as Vice President of Technical Operations.
In his role, Mr. Page will be
responsible for managing all aspects of Sharps' engineering
operations. His primary focus will be to provide the leadership and
technical expertise to support the prefillable syringe
collaboration with Nephron Pharmaceuticals at the InjectEZ
facility. These efforts will include the support for the injection
molding of the specialty components and the high speed assembly of
the prefillable syringe systems for all products. His initial
efforts will include the acceleration of the manufacturing
requirements that will produce the 1ml-long syringe platform and
the 10ml syringe product that will begin production later this
year. He will help oversee all training and manufacturing
development programs to support the rapid startup of the various
manufacturing cells for all products at the InjectEZ facility. Mr.
Page will also support Sharps’ broader technical operations
including the optimization and increased throughput at both the
InjectEZ facility and the operation in Hungary.
Robert Hayes, Chief Executive Officer,
commented: “Justin has a strong background in plastics engineering
and brings over 20 years of experience overseeing technical aspects
of injection molding including the medical device industry. I have
worked with Justin and the teams he has brought together over the
years and I consider him to be an expert in his field. He will
bring the technical expertise needed to support the advancement of
our products through the collaboration with Nephron. As we enter
into commercial sales and the next generation of our products,
Justin will play a major role in our success.”
Mr. Page brings 20 years of technical injection
molding and manufacturing experience in specialty packaging within
the medical device industry. Mr. Page has spent the last 12 years
with the Silgan Holdings Group where he served most recently as the
Plant Manager overseeing all aspects of technical and manufacturing
operations. Prior to Silgan, Mr. Page worked at Amcor Plastics
where he managed injection molding processes for large scale
medical device tool manufacturing. Mr. Page has a Bachelor’s of
Science Degree in Plastics Engineering Technology from Penn State,
Behrend College School of Engineering.
About Sharps TechnologySharps
Technology is a medical device and pharmaceutical packaging company
specializing in the development and manufacturing of innovative
drug delivery systems. The Company’s product lines focus on low
waste and ultra-low waste syringe technologies that incorporate
both passive and active safety features. These features protect
front line healthcare workers from life-threatening needle stick
injuries and protect the public from needle re-use. Sharps
Technology has extensive expertise in specialized prefilled syringe
systems and ready to use processing. The Company has a
manufacturing facility in Hungary and has partnered with Nephron
Pharmaceuticals to expand its manufacturing capacity in the US. For
additional information, please visit www.sharpstechnology.com.
Forward-Looking Statements:This
press release contains “forward-looking statements” Forward-looking
statements reflect our current view about future events. When used
in this press release, the words “anticipate,” “believe,”
“estimate,” “expect,” “future,” “intend,” “plan,” or the negative
of these terms and similar expressions, as they relate to us or our
management, identify forward-looking statements. Such statements,
include, but are not limited to, statements contained in this press
release relating to our business strategy, our future operating
results and liquidity, and capital resources outlook.
Forward-looking statements are based on our current expectations
and assumptions regarding our business, the economy, and other
future conditions. Because forward–looking statements relate to the
future, they are subject to inherent uncertainties, risks, and
changes in circumstances that are difficult to predict. Our actual
results may differ materially from those contemplated by the
forward-looking statements. They are neither statements of
historical fact nor guarantees of assurance of future performance.
We caution you therefore against relying on any of these
forward-looking statements. Important factors that could cause
actual results to differ materially from those in the
forward-looking statements include, without limitation, our ability
to raise capital to fund continuing operations; our ability to
protect our intellectual property rights; the impact of any
infringement actions or other litigation brought against us;
competition from other providers and products; our ability to
develop and commercialize products and services; changes in
government regulation; our ability to complete capital raising
transactions; and other factors relating to our industry, our
operations and results of operations. Actual results may differ
significantly from those anticipated, believed, estimated,
expected, intended, or planned. Factors or events that could cause
our actual results to differ may emerge from time to time, and it
is not possible for us to predict all of them. We cannot guarantee
future results, levels of activity, performance, or achievements.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
Investor Relations:
US Investor Relations: Adam Holdsworth,
Managing DirectorTraDigital IRadam@tradigitalir.com
Or
Investor Relations:Dave
GentryRedChip Companies Inc.1-800-RED-CHIP (733-2447)Or
407-491-4498STSS@redchip.com
Sharps Technology (NASDAQ:STSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sharps Technology (NASDAQ:STSS)
Historical Stock Chart
From Jul 2023 to Jul 2024